Prospective study of Mean Arterial Blood Pressure Augmentation in the Treatment of Spinal Cord Injuries (MAP study):

An EAST Multicenter Trial Proposal

Principle investigator: Chance Spalding DO PhD
Co-investigator: Aimee LaRiccia DO

Background significance

The pathophysiology of spinal cord injuries involves both mechanical forces (compression, distraction and transection) and nutrient delivery systems (blood flow, oxygenation).[1,2] A critical aspect of spinal cord recovery is maintaining adequate blood flow to the injured neural tissue.[1,2] Augmentation of blood pressure with elevation of mean arterial pressure (MAP) is part of the modern treatment for traumatic spinal cord injuries (SCI).[1, 3-7]

Loss of blood flow autoregulation within the injured spinal cord creates an environment for continued ischemia that can be seen with laser speckle contrast imagery.[8] Elevated MAP goals (>85 mmHg) for four to seven days post injury correlate with improved neurological outcomes, measured by American Spinal Injury Association (ASIA) scores.[1, 3-7] Spinal cord hyperperfusion protocols (Appendix A) appear to be an essential part of early spinal cord injury treatment showing improved neurologic outcomes.[1, 3-7]

Spinal cord hyperperfusion protocols start with fluid resuscitation and vasopressor support (Appendix A). The Consortium for Spinal Cord Medicine recommends the use of vasopressors dopamine, norepinephrine or phenylephrine based on injury location.[5,7] Initiation of therapies in injured patients does not appear to be without risk. Complications of vasopressor use are more common in elderly trauma patients and are typified by arrhythmias and elevated cardiac enzymes.[9-12] Along with treatment risks, other details regarding treatment timing, duration and need to achieve set MAP goals during the entire 72-96 hours are lacking in the current literature.

Optimal hyperperfusion care during early spinal cord injury therapy is MAP > 85 mmHg 100% of the treatment protocol (72-96 hours). Even when patients are cared for in intensive care units at level one trauma centers, these goals occur only 75% of the time.[1,13] Hyperperfusion goals are even less likely to occur in patients requiring operative fixation, with one recent study showing 100% of SCI patients had a MAP < 85 during operative interventions.[14]

Approximately 80% of all SCIs occur concurrently with polytrauma, creating tenuous resuscitative circumstances in the setting of multiple potential sources of shock.[15-17] Traumatic SCI treatment typically includes early operative intervention (within first 24 hours post injury) to increase the odds of neurological improvement.[2] Previous studies have demonstrated that the desire for both spinal cord hyperperfusion and early spine fixation creates competing treatment priorities.[14] It has also been shown that transferred trauma patients also have unique unknown treatment specifics as the time difference between time of injury and blood pressure augmentation protocols can vary widely. Specifically cited from a 40 patient case series, community/transferring hospitals had 50% of MAP recordings less than 80mmHg and 20% of MAP recordings less than 80mmHg during transport (18). The interplay between
hyperperfusion timing, spine fixation and complications associated with hyperperfusion therapies during early SCI treatment are yet to be delineated. We feel this is largely due to the lack of large prospective data registries specifically designed to investigate this population and the investigative questions to follow.

**Specific aims:**

**Primary aim:**
1. Determine the amount of time (hours) patients on MAP protocol reach the goal of a MAP >85mmHg.
2. Determine the proportion of SCI patients that meet a MAP goal of >85mmHg for 90% of their treatment duration.

**Secondary aims:**
1. Compare the MAP outcomes (time patients have MAP < 85mmHg and proportion of time MAP goal < 85mmH) between trauma transfers and direct from scene patients.
2. Determine the cardiogenic complications (atrial fibrillation, ventricular arrhythmia and troponin elevation) of patients on MAP treatment with vasopressor medications.
3. Determine how polytrauma (based on ISS scores) influences MAP treatment.

**Experimental design**

1. **Inclusion criteria:**
   - Blunt trauma patients with spinal cord injury on MAP protocol
   - Age > 18
   - Admission date 10/1/2021-10/1/2022
2. **Exclusion criteria:**
   - Patients under the age of 18
   - Non trauma patients undergoing surgical decompression and/or stabilization on MAP protocol
   - Incomplete neurological exam documented on hospital admission
   - Pregnant
   - Prisoners
   - Penetrating trauma
3. **Therapeutic interventions**
   a. Prospective observation study. Patients will be managed according to the standards of the treating physicians or institutional protocols.

**Outcomes**

**Primary:**
1. Neurologic improvement (specifically change in ASIA score) from admission to post-map protocol and at discharge in those patients who met a MAP goal for greater
than 75% of their first 24 hours of treatment.

Secondary:
1. Determine the complications of vasopressor use in maintenance of elevated MAP goals.
2. Determine in influence pre-receiving hospital transfer treatment and time effects the over the overall course of SCI patients in regard to neurological outcomes.
3. Determine the patient specific, injury specific and treatment specific influences on neurologic improvement in SCI patients.

Variable list

Demographics, injury and hospitalization variables, operative-specific variables, neurological exam values, MAP data, vasopressor data, daily laboratory and vital signs, complications, and invasive procedure data will be collected for patients included in this study. MAP values will be recorded on an hourly basis with time 0 representing the first MAP value recorded post-injury. Each subsequent hour will be recorded, any missing hours will be noted in the data collection tool.

These data points are collected as standard of care for patients treated for traumatic SCI at most trauma centers. Only the designated study staff will have access to the REDCap database created solely for use in this study.

Data collection and Statistics

Multi-institution study including level 1 and level 2 trauma centers. This will be a prospective review of retrospectively collected data to identify all trauma patients being treated with hyperperfusion protocols for spinal cord injury at their respective institution. Patients will be identified from the trauma registry at each institution. A review of the institutions electronic medical record system will be utilized to calculate the neurological exam score. The investigators will also utilize their respective trauma registries and electronic medical record system to obtain the complete list of study variables.

Simple comparisons of continuous variables between independent groups (neurologic improvement vs no improvement) will be made using two-sided, two-sample t-tests. For ordinal variables, simple comparisons will use Wilcoxon two-sample tests. Categorical or dichotomous variables will be compared between independent groups using chi-square tests. Models that control for relevant covariates will be based on logistic regression for dichotomous outcomes and analysis of covariance (ANCOVA) for continuous outcomes. When sample estimates (e.g. average fraction of time MAP <85) are presented, 95% confidence intervals will be constructed around each point estimate. Intraoperative MAP values will be analyzed similarly to non-operative MAP values as above. Descriptive statistics will be reported as mean +/- standard deviation for continuous variables, and as frequencies with percentages for categorical or dichotomous variables. Logistic regression was used to model neurological improvement (as a dichotomous outcome) as a function of a set of potential predictors.
Area under curve (AUC) calculation will be performed for each patient as a function of time spent below a MAP of 85 mmHg. Where \(a_1:b_1\) are the first time points where the patients MAP value crosses below MAP of 85 mmHg. \(f(x)\) represents a single patients MAP pressure curve for 96 hours of the hyperperfusion therapy.

\[
\text{AUC} = \int_{a_1}^{b_1} f(x) \, dx + \int_{a_2}^{b_2} f(x) \, dx + \cdots + \int_{a_x}^{b_x} f(x) \, dx
\]

Power analysis:

Gaudin et al (J Neurosurg Spine 32:127-132, 2020) found that episodes of relative intraoperative hypotension (MAP < 85 mm Hg) occurred 51.9% of the total OR time in their study. If our retrospective study were to find that result, our sample of \(n=200\) patients would provide an estimate precision (i.e. 95% confidence interval) of (45.0%, 58.8%).

**Consent procedures**

This is a prospective observational study in which patients are managed according to the discretion of the institution, so a waiver of consent is requested. With transfer of data to the REDcap form there will be no patient identifiers.

**Risk Benefit analysis**

Given the observational nature of the study, the only potential risk associated with this study is loss of confidentiality, which will be minimized by limiting access to data and de-identifying data within the REDcap data collection tool. The information from this study will be used to help to improve care by providing a clearer understanding of how early hyperperfusion therapy correlates with neurologic outcomes in patients with spinal cord injuries.

**References**


